central nervous system

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

Authors: Aylin Yilmaz, Åsa Mellgren, Dietmar Fuchs, Staffan Nilsson, Kaj Blennow, Henrik Zetterberg & Magnus Gisslén

Journal: Infectious Diseases

Year Published: 2019

Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because of its […]

Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?

Authors: A Winston, L Garvey, E Scotney, D Yerrakalva, J M Allsop, E C Thomson, V P B Grover, J Main, J I Cox, M Wylezinska, S D Taylor-Robinson

Journal: Journal of Viral Hepatitis

Year Published: 2010

Central nervous system (CNS) manifestations of chronic hepatitis C virus (HCV) and chronic human immune deficiency virus-1 (HIV-1) infections have been reported, but the impact of acute HCV infection on the CNS is unknown. A total […]

Back to Publications

Cogstate
© 2025 Cogstate Ltd.

Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.